Compared to CD4+ T-cells from untreated MS patients, CD4+ T-cells from IFN-β-treated patients expressed decreased levels of immunoregulatory IL10 and TH1 TF HLX1 and higher levels of TH1 TF TBX21 and pro-inflammatory TNF. The gene discussed is CD4; the disease is myeloid sarcoma.